Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.1 USD | -0.33% | -2.81% | -47.64% |
08/05 | Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating | MT |
08/05 | Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q1 Revenue $11.7M | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.64% | 63Cr | |
+37.58% | 71TCr | |
+32.59% | 58TCr | |
-3.22% | 36TCr | |
+20.07% | 33TCr | |
+5.31% | 29TCr | |
+16.91% | 24TCr | |
-3.56% | 21TCr | |
+10.40% | 21TCr | |
+9.27% | 17TCr |
- Stock Market
- Equities
- EYPT Stock
- News EyePoint Pharmaceuticals, Inc.
- Eyepoint Pharmaceuticals Insider Sold Shares Worth $415,200, According to a Recent SEC Filing